An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs

Experimental Cell Research

Volumn 248, Issue 2, 1999, Pages 457-472

  Laín, Sonia ^b   Midgley, Carol ^b   Sparks, Alison ^b   Lane, E Birgitte ^a   Lane, David P ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NONE

Author keywords

HDM2; Leptomycin B; P53; POD; U1A

Indexed keywords

CELL PROTEIN; LEPTOMYCIN B; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ARTICLE; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; FIBROBLAST; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STABILITY;

MURINAE; NES;

EID: 0038298110     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4433     Document Type: Article

References (85)

1. Ahn J. H., Hayward G. S. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 6:1997;4599-4613.
2. Ascoli C. A., Maul G. G. Identification of a novel nuclear domain. J. Cell. Biol. 112:1991;785-795.
3. Boelens W., Jansen E. J. R., van Venrooij W. J., Stripecke R., Mattaj I. W., Gunderson S. I. The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own pre-mRNA. Cell. 72:1993;881-892.
4. Bottger A., Bottger V., Garcia-Echeverria C., Chene P., Hochkeppel H. K., Sampson W., Ang K., Howard S. F., Picksley S. M., Lane D. P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269:1997a;744-756.
5. Bottger A., Bottger V., Sparks A., Liu W-L., Howard S. F., Lane D. Peptide aptamers that disrupt the interaction between mdm2 and p53 in vivo activate p53 dependent transcription and inhibit p53 degradation. Curr. Biol. 7:1997b;860-869.
6. Bottger V., Bottger V., Howard S. F., Picksley S. M., Chene P., Garcia-Echeverria C., Hochkeppel H. K., Lane D. P. Identification of novel mdm2 binding peptides by phage display. Oncogene. 13:1996;2141-2147.
7. Bueso-Ramos C. E., Manshouri T., Haidar M. A., Yang Y., McCown P., Ordonez N., Glassman A., Sneige N., Albitar M. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37:1996;179-188.
8. Bueso-Ramos C. E., Yang Y., deLeon E., McCown P., Stass S. A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 82:1993;2617-2623.
9. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370:1994;220-223.
10. Carvalho T., Seeler J-S., Öhrman K., Jordan P., Petterson U., Akusjärvi G., Carmo-Fonseca M., Dejean A. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell. Biol. 131:1995;45-56.
11. Chen J., Marechal V., Levine A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
12. Dobbelstein M., Roth J., Kimberly W. T., Levine A. J., Shenk T. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J. 16:1997;4276-4284.
13. Doucas V., Ishov A. M., Romo A., Juguilon H., Weitzman M. D., Evans R. M., Maul G. G. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:1996;196-207.
14. Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
15. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-425.
16. Engel K., Kotlyarov A., Gaestel M. Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J. 17:1998;3363-3371.
17. Everett R. D., Gerd G. G. HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13:1994;5062-5069.
18. Fontoura B. M. A., Atienza C. A., Sorokina E. A., Morimoto T., Carrol R. B. Cytoplasmic p53 polypeptide is associated with ribosomes. Mol. Cell. Biol. 17:1997;3146-3154.
19. Fornerod M., Ohno M., Yoshida M., Mattaj I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 90:1997a;1051-1060.
20. Fornerod M., van Deursen J., van Baal S., Reynolds A., Davis D., Murti K. G., Fransen J., Grosveld G. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J. 16:1997b;807-816.
21. Fredersdorf S., Milne A. W., Hall P. A., Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am. J. Pathol. 148:1996;825-835.
22. Freedman D. A., Levine A. J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
23. Fritsche M., Haessler C., Bradner G. Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA damaging agents. Oncogene. 8:1993;307-318.
24. Fu L., Benchimol S. Participation of the human p53 3′UTR in translational repression and activation following g-irradiation. EMBO J. 16:1997;4117-4125.
25. Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M., Nishida E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 390:1997;308-311.
26. Fukuda M., Gotoh I., Gotoh Y., Nishida E. Cytoplasmic localisation of mitogen-activated protein kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J. Biol. Chem. 271:1996;20024-20028.
27. Gerace L. Nuclear export signals and the fast track to the cytoplasm. Cell. 82:1995;341-344.
28. Gossen M., Bujard H. Tight control of gene expression on mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89:1992;5547-5551.
29. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science, 268:1995;1766-1769.
30. Hagting A., Karlsson C., Clute P., Jackman M., Pines J. MPF localisation is controlled by nuclear export. EMBO J. 17:1998;4127-4138.
31. Hamm J., Mattaj I. W. Monomethylated cap structures facilitate RNA export from the nucleus. Cell. 63:1990;109-118.
32. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
33. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
34. Haupt Y., Rowan S., Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10:1995;1563-1571.
35. Hupp T. R., Sparks A., Lane D. P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
36. Ishioka C., Englert C., Winge P., Yan Y. X., Engelstein M., Friend S. H. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene. 10:1995;1485-1492.
37. Jiang W-Q., Szekely L., Klein G., Ringertz N. Intranuclear redistribution of SV40T, p53, and PML in a conditionally SV40T-immortalized cell line. Exp. Cell. Res. 229:1996;289-300.
38. Kambach C., Mattaj I. W. Intracellular distribution of the U1A protein depends on active transport and nuclear binding to U1 sn RNA. J. Cell. Biol. 118:1992;11-21.
39. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
40. Kastan M. B., Zhan Q., el-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., Fornace A. J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
41. Kenny M. K., Schlegel U., Furneaux H., Hurwitz J. The role of human single-stranded DNA binding protein and its individual subunits in simian virus 40 DNA replication. J. Biol. Chem. 265:1990;7693-7700.
42. Kubbutat M. H., Jones S. N., Vousden K. H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
43. Kudo N., Wolff B., Sekimoto T., Schreiner E. P., Yoneda Y., Yanagida M., Horinouch S., Yoshida M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell. Res. 242:1998;540-547.
44. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
45. Lane D. P. Cancer: p53, guardian of the genome. Nature. 358:1992;15-16.
46. Lane D. P. Awakening angels. Nature. 394:1998;616-617.
47. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235-1246.
48. Lu X., Burbidge S. A., Griffin S., Smith H. M. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Oncogene. 13:1996;413-418.
49. Lu X., Lane D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes. Cell. 75:1993;765-778.
50. Lührmann R., Kastner B., Bach M. Structure of spliceosomal sn RNPs and their role in pre-mRNA splicing. Biochim. Biophys. Acta. 1087:1990;265-292.
51. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1984;1689-1694.
52. Maul G. G., Ishov A. M., Everett R. D. Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1. Virology. 217:1996;67-75.
53. Midgley C. A., Fisher C. J., Bartek J., Vojtesek B., Lane D., Barnes D. M. Analysis of p53 expression in human tumours: An antibody raised against human p53 expressed inEscherichia coli. J. Cell. Sci. 101:1992;183-189.
54. Midgley C. A., Lane D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
55. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
56. Neville M., Stutz F., Lee L., Davis L. I., Rosbash M. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr. Biol. 7:1997;767-775.
57. Nishi K., Yoshida M., Fujiwara D., Nishikawa M., Horinouchi S., Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269:1994;6320-6324.
58. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
59. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
60. Ossareh-Nazari B., Bachelerie F., Dargemont C. Evidence for a role of CRM1 in signal mediated nuclear protein export. Science. 278:1997;141-144.
61. Patterson, I. Hinterberger, M. Mimori, T. Gottlieb, E. Steitz, J. A. 1984, The structure of mammalian nucleoproteins. Identification of multiple protein components reactive with anti-(U1) ribonucleoprotein and anti-Sm autoantibodies, J. Biol. Chem. 259, 5907.
62. Picksley S. M., Vojtesek B., Sparks A., Lane D. P. Immunochemical analysis of the interaction of p53 with MDM2: Fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9:1994;2523-2529.
63. Piette J., Neel H., Marechal V. Mdm2: Keeping p53 under control. Oncogene. 15:1997;1001-1010.
64. Puvion-Dutilleul F., Chelbi-Alix M. K., Koken M., Quignon F., Puvion E., de Thé H. Adenovirus infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Exp. Cell Res. 218:1995;9-16.
65. Querido E., Marcellus R. E., Lai A., Charbonneau R., Teodoro J. G., Ketner G., Branton P. E. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J. Virol. 71:1997;3788-3798.
66. Renzing J., Lane D. P. p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts. Oncogene. 10:1995;1865-1868.
67. Roth J., Dobbelstein M., Freedman D. A., Shenk T., Levine A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodefficiency virus rev protein. EMBO J. 17:1998;554-564.
68. Somers K. D., Merrick M. A., Lopez M. E., Incognito L. S., Schechter G. L., Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 52:1992;5997-6000.
69. Stade K., Ford C. S., Guthrie C., Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell. 90:1997;1041-1050.
70. Stephen C. W., Helminen P., Lane D. P. Characterization of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J. Mol. Biol. 248:1995;58-78.
71. Szekely L., Pokrovskaja K., Jiang W-Q., de Thé H., Ringertz N., Klein G. The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J. Virol. 70:1996;2562-2568.
72. Szostecki C., Guldner H. H., Netter H. J., Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145:1990;4338-4347.
73. Toone W. M., Kuge S., Samuels M., Morgan B. A., Toda T., Jones N. Regulation of the fission yeast factor Pap1 by oxidative stress: Requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Specimen. Genes Dev. 12:1998;1453-1463.
74. Toyoshima F., Moriguchi T., Wada A., Fukuda M., Nishida E. Nuclear export of cyclin B1 and its possible role in DNA damage-induced G2 checkpoint. EMBO J. 17:1998;2728-2735.
75. Vojtesek B., Dolezalova H., Lauerova L., Svitakova M., Havlis P., Kovarik J., Midgley C. A., Lane D. P. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene. 10:1995;389-393.
76. Walker K. K., Levine A. J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA. 93:1996;15335-15340.
77. Waseem N. H., Lane D. P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA): Structural conservation and detection of a nucleolar form. J. Cell. Sci. 96:1990;121-129.
78. Weis K., Rambaud S., Lavau C., Jansen J., Carvalho T., Carmo-Fonseca M., Lamond A., Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell. 76:1994;345-356.
79. Wilcock D., Lane D. P. Localization of p53, retinoblastoma and host proteins at sites of viral replication in herpes-infected cells. Nature. 349:1991;429-431.
80. Wolff B., Sanglier J. J., Wang Y. Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Curr. Biol. 4:1997;139-147.
81. Wu X., Bayle J. H., Olson D., Levine A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
82. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobagashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-706.
83. Yoshida E., Komiyama K., Naito K., Watanabe Y., Takamiya K., Okura A., Funaishi K., Kawamura K., Funayama S., Umezawa I. Antitumor effect of kazusamycin B on experimental tumors. J. Antibiotics. 40:1987;1596-1604.
84. Yoshida M., Nishikawa M., Nishi K., Abe K., Horinouchi S., Beppu T. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp. Cell. Res. 187:1990;150-156.
85. Zhan Q., Carrier F., Fornace A. J. Jr. Induction of cellular p53 by DNA-damaging agents and growth arrest. Mol. Cell. Biol. 13:1993;4242-4250.